[1]余呈丽,李瑞娟.无偿献血人群血液筛查后乙型肝炎病毒传播的残余风险评估[J].医学信息,2024,37(13):49-51,55.[doi:10.3969/j.issn.1006-1959.2024.13.009]
 Residual Risk Assessment of Hepatitis B Virus Transmission After Blood Screening in Voluntary Blood Donors.Residual Risk Assessment of Hepatitis B Virus Transmission After Blood Screening in Voluntary Blood Donors[J].Journal of Medical Information,2024,37(13):49-51,55.[doi:10.3969/j.issn.1006-1959.2024.13.009]
点击复制

无偿献血人群血液筛查后乙型肝炎病毒传播的残余风险评估()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年13期
页码:
49-51,55
栏目:
公共卫生信息学
出版日期:
2024-07-01

文章信息/Info

Title:
Residual Risk Assessment of Hepatitis B Virus Transmission After Blood Screening in Voluntary Blood Donors
文章编号:
1006-1959(2024)13-0049-04
作者:
余呈丽李瑞娟
(曲靖市中心血站,云南 曲靖 655000)
Author(s):
Residual Risk Assessment of Hepatitis B Virus Transmission After Blood Screening in Voluntary Blood Donors
(Qujing City Center Blood Center,Qujing 655000,Yunnan,China)
关键词:
无偿献血乙型肝炎病毒 HBsAg HBV DNA残余风险
Keywords:
Voluntary blood donorsHepatitis B virusHBsAgHBV DNAResidual risk
分类号:
R457.1;R512.6+2
DOI:
10.3969/j.issn.1006-1959.2024.13.009
文献标志码:
A
摘要:
目的 初步评估曲靖地区无偿献血人群血液筛查后乙型肝炎病毒传播的残余风险度,评价现行筛查模式,对下一步血液筛查工作的改进提供数据基础。方法 统计2020年1月1日-2022年12月31日曲靖市中心血站无偿献血者乙型肝炎病毒表面抗原(HBsAg)以及HBV DNA的筛查数据,采用发病率-窗口期比率数学模型(yield/WP ratio model)分别评估初次献血者及重复献血乙型肝炎病毒传播的残余风险。结果 2020-2022年,曲靖市中心血站共对173 084人次进行乙型肝炎筛查,其中初次献血者79 073人次,重复献血者94 011人次。ELISA检测HBsAg阳性340人次(初次献血者阳性273人次,重复献血者阳性67人次),核酸检测HBV DNA单阳68人次(初次献血者阳性41人次,重复献血者阳性27人次)。初次献血者HBsAg残余风险为10.21/10万人次,重复献血者HBsAg残余风险为3.4/10万人次;初次献血者HBV DNA残余风险为2.04/10万人次,重复献血者HBV DNA残余风险为0.68/10万人次。结论 曲靖地区无偿献血人群中重复献血者的乙型肝炎病毒传播残余风险低于初次献血者,增加一次核酸检测能够明显降低乙型肝炎病毒传播的残余风险,对保障血液安全,预防输血感染乙型肝炎病毒具有重要意义。现行筛查模式下,曲靖地区无偿献血人群乙型肝炎病毒传播残余风险较低,处于安全水平。
Abstract:
Objective To preliminarily evaluate the residual risk of hepatitis B virus transmission after blood screening among voluntary blood donors in Qujing area, evaluate the current screening model, and provide data basis for the improvement of blood screening work in the next step.Methods The screening data of hepatitis B virus surface antigen (HBsAg) and HBV DNA in voluntary blood donors in Qujing Central Blood Station from January 1, 2020 to December 31, 2022 were collected. The yield/WP ratio model was used to evaluate the residual risk of hepatitis B virus transmission in primary blood donors and repeated blood donors.Results From 2020 to 2022, a total of 173 084 people were screened for hepatitis B in Qujing Central Blood Station, including 79 073 initial blood donors and 94 011 repeated blood donors. There were 340 HBsAg positive cases detected by ELISA (273 positive cases in initial blood donors and 67 positive cases in repeated blood donors), and 68 HBV DNA positive cases detected by nucleic acid test (41 positive cases in initial blood donors and 27 positive cases in repeated blood donors). The residual risk of HBsAg in initial blood donors was 10.21/100 000, and the residual risk of HBsAg in repeated blood donors was 3.4/100 000. The residual risk of HBV DNA in first-time blood donors was 2.04/100 000, and the residual risk of HBV DNA in repeated blood donors was 0.68/100 000.Conclusion The residual risk of hepatitis B virus transmission in repeated blood donors in Qujing area is lower than that in first-time blood donors. Increasing one nucleic acid test can significantly reduce the residual risk of hepatitis B virus transmission, which is of great significance to ensure blood safety and prevent transfusion infection with hepatitis B virus. Under the current screening mode, the residual risk of hepatitis B virus transmission among voluntary blood donors in Qujing area is low and at a safe level.

参考文献/References:

[1]高志良,朱翔.怎样实现乙型肝炎临床治愈[J].实用肝脏病杂志,2019,22(3):305-308.[2]刘智鹏,王明达,陈志宇,等.乙型肝炎相关性肝癌的一级预防[J].肝胆外科杂志,2021,29(5):341-344.[3]段学云,左江涛,焦东丽,等.输血传播人类免疫缺陷病毒及乙型肝炎病毒和丙型肝炎病毒的风险评估[J].中国医药,2015,10(4):606-608.[4]李俊英,王艺芳,葛文超,等.核酸检测系统的应用分析及质量监控[J].中国卫生检验杂志,2019,29(13):1656-1657,1660.[5]于志军,邓雪莲,高慧卉,等.血清学检测与核酸检测在献血者血液筛查中的相关性研究[J].实用预防医学,2014,21(5):532-534.[6]张锋,黄国永,孟忠华,等.浙江省血站核酸集中化检测质量评价体系的建立[J].中国卫生检验杂志,2020,30(5):635-637.[7]Schreiber GB,Busch MP,Kleinman SH,et al.The risk of transfusion-transmitted viral infections.The retrovirus epidemiology donor study[J].N Engl J Med,1996,334(26):1685-1690.[8]World Health Organization.WHO expert committee on biological standardization,sixty-seventh report[M].Geneva.World Health Organization,2017(WHO technical report series;no.1004).[9]徐明华,代润,龚华斐,等.烟台地区血液筛查乙型肝炎病毒残余风险评估[J].国际免疫学杂志,2021,44(3):258-262.[10]刘永霞,刘欢,刘燕,等.全自动核酸检测分析系统在无偿献血者病毒检测中的应用[J].实用临床医药杂志,2020,24(23):113-115.[11]曾劲峰,赵钰,王立林.新发突发传染病防控中对粤港澳桂片区输血安全的思考[J].分子诊断与治疗杂志,2021,13(1):1-3,16.[12]何子毅,陈庆恺,陈少彬,等.四种血液安全筛查模式对经血传播病毒残余风险的评估[J].中国输血杂志,2018,31(2):140-143.[13]胡俊华,秦莉,刘娟,等.术前/输血前筛查血源性传播疾病风险检测方法比较的多中心研究[J].中华检验医学杂志,2023,46(1):32-37.[14]余鼎,段艳,张燕,等.两种数学模型用于重复供血浆人群丙型肝炎病毒及人类免疫缺陷病毒残余风险评估的比较[J].中国生物制品学杂志,2017,30(11):1220-1222.[15]O’Brien SF,Yi QL,Fan W,et al.Residual risk of HIV,HCV and HBV in Canada[J].Transfus Apher Sci,2017,56(3):389-391.[16]黄敏,李燕,张立波,等.南京地区无偿献血人群输血传播HBV残余风险度评估研究[J].临床输血与检验,2022,24(4):454-458.[17]Zou S,Fang CT,Dodd RY.A method for estimating incidence rate of infectious diseases among first-time blood donors[J].Transfusion,2008,48(9):1827-1832.[18]刘宇宁,贾尧,王海英,等.重复献血者HBV窗口期残余风险评估及趋势研究[J].中国输血杂志,2021,34(11):1231-1234.[19]祝宏,董杰,凌霞,等.杭州市无偿献血者乙型肝炎病毒感染及其传播残余风险分析[J].预防医学,2022,34(1):63-65,69.[20]胡贵宾,郑艳梅,释艳华.襄阳地区ELISA+NAT模式降低HBV输血残余风险的效果分析[J].临床输血与检验,2018,20(3):273-275.

相似文献/References:

[1]蔡华英,赖世平.自贡市无偿献血血液检测不合格率构成分析[J].医学信息,2018,31(04):115.[doi:10.3969/j.issn.1006-1959.2018.04.040]
 CAI Hua-ying,LAI Shi-ping.Composition Analysis of Unqualified Rate of Blood Test in Blood Donation without Repayment in Zigong City[J].Journal of Medical Information,2018,31(13):115.[doi:10.3969/j.issn.1006-1959.2018.04.040]
[2]钱熠辉,彭 琼.乙型肝炎病毒感染与结直肠腺瘤的相关性研究[J].医学信息,2019,32(04):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
 QIAN Yi-hui,PENG Qiong.Correlation between Hepatitis B Virus Infection and Colorectal Adenoma[J].Journal of Medical Information,2019,32(13):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
[3]杨美玲,黄荷凤.HBV暴露对子代影响的研究进展[J].医学信息,2019,32(10):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
 YANG Mei-ling,HUANG He-feng.Advances in Research on the Effects of HBV Exposure on Offspring[J].Journal of Medical Information,2019,32(13):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
[4]唐细田,肖 琳,徐彤慧.化学发光法和酶联免疫法在乙型肝炎病毒血清学检验中的效果比较[J].医学信息,2019,32(22):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
 TANG Xi-tian,XIAO Lin,XU Tong-hui.Comparison of the Effects of Chemiluminescence and Enzyme-linked Immunosorbent Assay on Serological Test of Hepatitis B Virus[J].Journal of Medical Information,2019,32(13):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
[5]唐福明.早期护理干预对降低血站采血点无偿献血者献血反应的影响[J].医学信息,2020,33(01):185.[doi:10.3969/j.issn.1006-1959.2020.01.062]
 TANG Fu-ming.Effect of Early Nursing Intervention on Reducing Blood Donation Response of Unpaid Blood Donors at Blood Stations[J].Journal of Medical Information,2020,33(13):185.[doi:10.3969/j.issn.1006-1959.2020.01.062]
[6]苏振华.乙肝病毒标记物阳性表型血清标本乙型肝炎病毒HBV-DNA临床检验分析[J].医学信息,2020,33(04):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]
 SU Zhen-hua.Clinical Analysis of Hepatitis B Virus HBV-DNA in Serum Specimen with Hepatitis B Virus Markers Positive[J].Journal of Medical Information,2020,33(13):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]
[7]党便利,孙永涛,康文臻.HBcrAg在慢性乙型肝炎中研究进展[J].医学信息,2020,33(17):23.[doi:10.3969/j.issn.1006-1959.2020.17.007]
 DANG Bian-li,SUN Yong-tao,KANG Wen-zhen.Research Progress of HBcrAg in Chronic Hepatitis B[J].Journal of Medical Information,2020,33(13):23.[doi:10.3969/j.issn.1006-1959.2020.17.007]
[8]文 静.HBV感染患者血清25(OH)D3含量与HBV DNA载量的相关性[J].医学信息,2022,35(21):81.[doi:10.3969/j.issn.1006-1959.2022.21.018]
 WEN Jing.Correlation Between Serum 25(OH)D3 Content and HBV DNA Load in Patients with HBV Infection[J].Journal of Medical Information,2022,35(13):81.[doi:10.3969/j.issn.1006-1959.2022.21.018]
[9]张 胤,刘妍妍.无偿献血志愿者队伍的发展展望[J].医学信息,2021,34(09):51.[doi:10.3969/j.issn.1006-1959.2021.09.013]
 ZHANG Yin,LIU Yan-yan.Prospects for the Development of Unpaid Blood Donation Volunteers[J].Journal of Medical Information,2021,34(13):51.[doi:10.3969/j.issn.1006-1959.2021.09.013]
[10]帅苍南,张玉亭,刘 敏,等.抗慢性乙型肝炎肝纤维化中成药研究进展[J].医学信息,2022,35(08):38.[doi:10.3969/j.issn.1006-1959.2022.08.010]
 SHUAI Cang-nan,ZHANG Yu-ting,LIU Min,et al.Research Progress of Anti-chronic Hepatitis B Liver Fibrosis Chinese Patent Medicine[J].Journal of Medical Information,2022,35(13):38.[doi:10.3969/j.issn.1006-1959.2022.08.010]

更新日期/Last Update: 1900-01-01